CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 10 enrolled
Drug / intervention
Wellbutrin SR 300Mg Extended-Release Tabletdrug
Likely dose
Wellbutrin SR 300Mg Extended-Release Tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03126682
NCT03126682Phase 4Completed
CompareCT.gov

Effect of Bupropion on Seizure Threshold in Depressed Patients

Duke University·interventional·Posted Apr 24, 2017·Updated Jul 10, 2019

In Brief

A Phase 4 clinical trial evaluating Wellbutrin SR 300Mg Extended-Release Tablet for MDD. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The purpose of the study is to examine the effect of bupropion on seizure threshold and duration in depressed patients receiving right unilateral ultra-brief electroconvulsive therapy (ECT). The investigators plan to recruit 10 patients into the study, administer sustained release (SR) bupropion 4 hours prior to receiving ECT. The investigators plan to compare the seizure threshold and seizure durations between ECT sessions with and without bupropion administration. The study's implication is to examine how ECT can be optimized by rational combination with medications that lower seizure threshold.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMDD
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedApr 24, 2017
Enrollment StartAug 25, 2017
Primary CompletionMay 31, 2018
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 9.2 years ago

Interventions

Wellbutrin SR 300Mg Extended-Release Tabletdrug

Wellbutrin SR 300Mg Extended-Release Tablet